Remove FDA Remove Vaccines Remove White Paper
article thumbnail

From Pharmacy Counters to Classrooms: Building Confidence in Back-to-School Vaccinations

Pharmacy Times

Parental vaccine hesitancy, fueled by misinformation and logistical barriers, contributes to lower immunization rates and increased exemption rates. Parental vaccine hesitancy, fueled by misinformation and logistical barriers, contributes to lower immunization rates and increased exemption rates.

article thumbnail

Barriers are limiting UK childhood vaccination, say doctors

pharmaphorum

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out?

article thumbnail

FDA approves label updates for BMS’ CAR T cell therapies

Pharmaceutical Technology

Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates for its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) and Abecma (idecabtagene vicleucel; ide-cel) to treat multiple myeloma. Credit: Saiful52 / Shutterstock.

article thumbnail

FDA approves KalVista’s Ekterly for hereditary angioedema

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals’ Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE) in adults and in children aged 12 years and above.

FDA
article thumbnail

MAXONA Pharma seeks FDA approval for pain relief MAX-001

Pharmaceutical Technology

Using real-world data to support vaccine outreach and education Buy Reports Newsletters PT News MAXONA Pharma seeks FDA approval for pain relief MAX-001 MAX-001 provides both rapid onset and extended duration of analgesia. Credit: Inna Kot/Shutterstock.com.

FDA
article thumbnail

Piramal Pharma announces $90m investment to expand US sites

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Syngene’s expertise in the field is covered in this white paper. Syngene’s expertise in the field is covered in this white paper. You will receive an email shortly. Please check your inbox to download the Whitepaper. You will receive an email shortly.